143 related articles for article (PubMed ID: 18076045)
1. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
Wright KL; Robertson DA; Moyer MP; Ward SG
Int J Cancer; 2008 Apr; 122(8):1920-1. PubMed ID: 18076045
[No Abstract] [Full Text] [Related]
2. Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer".
Santoro A; Gazzerro P; Malfitano AM; Pisanti S; Laezza C; Bifulco M
Int J Cancer; 2008 Jul; 123(1):243-4. PubMed ID: 18395892
[No Abstract] [Full Text] [Related]
3. Rimonabant, obesity and diabetes.
Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
[TBL] [Abstract][Full Text] [Related]
4. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue.
Giraldo J
Drug Discov Today; 2010 Jun; 15(11-12):411-5. PubMed ID: 20447467
[TBL] [Abstract][Full Text] [Related]
5. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
6. End of the line for cannabinoid receptor 1 as an anti-obesity target?
Jones D
Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
[TBL] [Abstract][Full Text] [Related]
7. [The endocannabinoid system and treatment of obesity].
Aronsen L
Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
[TBL] [Abstract][Full Text] [Related]
8. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo V
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
[No Abstract] [Full Text] [Related]
9. Effect of rimonabant on weight and cardiometabolic risk factors.
Gadde KM
JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103
[No Abstract] [Full Text] [Related]
10. The effect of am 251, a cannabinoid CB1 receptor antagonist, on food intake in rats.
Rutkowska M
Acta Pol Pharm; 2004; 61(5):401-3. PubMed ID: 15747698
[TBL] [Abstract][Full Text] [Related]
11. [Sleep disorders associated with treatment with rimonabant].
Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
[No Abstract] [Full Text] [Related]
12. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
13. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
Ward SJ; Raffa RB
Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
[No Abstract] [Full Text] [Related]
14. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.
Greenhough A; Patsos HA; Williams AC; Paraskeva C
Int J Cancer; 2007 Nov; 121(10):2172-80. PubMed ID: 17583570
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
[TBL] [Abstract][Full Text] [Related]
17. CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).
Raffa RB; Ward SJ
J Clin Pharm Ther; 2012 Jun; 37(3):260-5. PubMed ID: 21740450
[TBL] [Abstract][Full Text] [Related]
18. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
Gadde KM; Allison DB
Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
[No Abstract] [Full Text] [Related]
20. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
